Аннотация:
Aim of the study was to explore the role of the FGF-23/sKlotho/sclerostin ratio disturbance in the determining of cardiovascular risk in end stage renal disease (ESRD) patients, receiving treatment with regular hemodialysis (ÍD) or hemodiafiltration (ÍDF) online in Russia. Materials and methods. 42 patients with ESRD, at the age of 18-55 years, treated with HD or HDF on line for at least 6 months, were examined. 22 (52.3[%]) patients received traditional HD, the remaining 20 (47.7[%]) - HDF online. In all the patients, in addition to a general examination, the serum levels of FGF-23, sKlotho, sclerostine (by ELISA), their associations with cardiovascular risk factors (left ventricular hypertrophy (LVH), acute coronary syndrome (ACS), serum troponin I levels) with the numbers of techniques (ECG; Eho-CGF (with calculation of left ventricular myocardium mass index (LVMMI), as well as the relative thickness of the walls of the left ventricle (RWT); sphygmography (central (aortal) blood pressur
Ключевые слова:
Fibroblast growth factor-23 (fgf-23); Hemodiafiltration; Hemodialysis; Hyperphosphatemia; Sclerostine; Secondary hyperparathyroidism; Soluble klotho; Troponin
beta glucuronidase; biological marker; bone morphogenetic protein; fibroblast growth factor; fibroblast growth factor 23; glycoprotein; Klotho protein; SOST protein, human; cardiovascular disease; chronic kidney failure; complication; genetic marker; hemodiafiltration; hemodialysis; human; hyperparathyroidism; inflammation; malnutrition; metabolism; risk factor; Russian Federation; Biomarkers; Bone Morphogenetic Proteins; Cardiovascular Diseases; Fibroblast Growth Factors; Genetic Markers; Glucuronidase; Glycoproteins; Hemodiafiltration; Humans; Hyperparathyroidism; Inflammation; Kidney Failure, Chronic; Malnutrition; Renal Dialysis; Risk Factors; Russia
Милованова Л. Ю. Людмила Юрьевна 1973-
Добросмыслов И. А. Игорь Александрович 1962-
Милованов Ю. С. Юрий Сергеевич 1944-
Таранова М. В. Марина Владимировна 1957-
Козлов В. В. Василий Владимирович 1974-
Милованова С. Ю. Светлана Юрьевна 1975-
Козевникова Е. И.
Milovanova L. Yu. Lyudmila Yuryevna 1973-
Dobrosmy'slov I. A. Igor` Aleksandrovich 1962-
Milovanov Yu. S. Yurij Sergeevich 1944-
Taranova M. V. Marina Vladimirovna 1957-
Kozlov V. V. Vasilij Vladimirovich 1974-
Milovanova S. Yu. Svetlana Yuryevna 1975-
Kozevnikova E. I.
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for...
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 90, Вып. 6 С. 48-54
2018
Статья
Fibroblast growth factor-23 (fgf-23) Hemodiafiltration Hemodialysis Hyperphosphatemia Sclerostine Secondary hyperparathyroidism Soluble klotho Troponin
beta glucuronidase biological marker bone morphogenetic protein fibroblast growth factor fibroblast growth factor 23 glycoprotein Klotho protein SOST protein, human cardiovascular disease chronic kidney failure complication genetic marker hemodiafiltration hemodialysis human hyperparathyroidism inflammation malnutrition metabolism risk factor Russian Federation Biomarkers Bone Morphogenetic Proteins Cardiovascular Diseases Fibroblast Growth Factors Genetic Markers Glucuronidase Glycoproteins Hemodiafiltration Humans Hyperparathyroidism Inflammation Kidney Failure, Chronic Malnutrition Renal Dialysis Risk Factors Russia
Aim of the study was to explore the role of the FGF-23/sKlotho/sclerostin ratio disturbance in the determining of cardiovascular risk in end stage renal disease (ESRD) patients, receiving treatment with regular hemodialysis (ÍD) or hemodiafiltration (ÍDF) online in Russia. Materials and methods. 42 patients with ESRD, at the age of 18-55 years, treated with HD or HDF on line for at least 6 months, were examined. 22 (52.3[%]) patients received traditional HD, the remaining 20 (47.7[%]) - HDF online. In all the patients, in addition to a general examination, the serum levels of FGF-23, sKlotho, sclerostine (by ELISA), their associations with cardiovascular risk factors (left ventricular hypertrophy (LVH), acute coronary syndrome (ACS), serum troponin I levels) with the numbers of techniques (ECG; Eho-CGF (with calculation of left ventricular myocardium mass index (LVMMI), as well as the relative thickness of the walls of the left ventricle (RWT); sphygmography (central (aortal) blood pressur